

RXLENS · MONTHLY SNAPSHOT


NHS Dispensing Snapshot — March 2026

NHS secondary-care medicines · England · latest available month

Measure	March 2026	Note
Indicative spend	£2,312,275,204	+15.2% vs February 2026
Distinct medicines	8,424	products dispensed
NHS Trusts reporting	191	in England
Rolling 12-month spend	£25,198,532,883	Apr 2025 – Mar 2026


NHS hospital pharmacies in England dispensed an indicative **£2,312,275,204** of medicines in March 2026, up 15.2% on February 2026. **Read the month-on-month change with care:** March has three more days than February, which accounts for much of the rise — the 12-month trend below is the more reliable guide. Over the full year, indicative spend totalled about **£25,198,532,883**.

NHS secondary-care medicines — indicative spend by month (England)

*Indicative spend by month — NHS secondary care, England.*

Where the money goes

The largest single products by indicative spend are high-cost biologics and specialist medicines — led by **Adalimumab 40mg/0.4ml (£72.8m)** in March 2026.



Top 10 products by indicative spend, March 2026.

Biggest movers, month on month

Largest increases and decreases in indicative spend, February 2026 → March 2026 (products above £100k):

Risers

Product	February 2026	March 2026	Change
Ixazomib 2.3mg capsules	£1.3m	£22.6m	+£21.3m
Ixazomib 3mg capsules	£2.0m	£23.4m	+£21.3m
Adalimumab 40mg/0.4ml	£58.4m	£72.8m	+£14.4m
Tafamidis 61mg capsules	£21.2m	£29.2m	+£8.0m
Generic Alyftrek 125mg/50mg/10mg tablets	£24.3m	£30.4m	+£6.1m
Pembrolizumab 100mg/4ml	£42.0m	£48.0m	+£6.0m

Fallers

Product	February 2026	March 2026	Change
Generic Alyftrek 50mg/20mg/4mg tablets	£9.8m	£3.6m	£-6.2m
Exagamglogene autotemcel 4million-13million cells/ml	£5.0m	£1.7m	£-3.3m
Dornase alfa 2.5mg/2.5ml nebuliser liquid ampoules	£4.7m	£2.1m	£-2.6m
Tocilizumab 162mg/0.9ml	£5.1m	£3.9m	£-1.2m
Emicizumab 150mg/1ml	£12.1m	£10.9m	£-1.2m
Ivacaftor 150mg tablets	£29.9m	£28.7m	£-1.2m

A note of caution: single-month jumps and falls in hospital data often reflect procurement, stocking and homecare-batching patterns rather than genuine changes in patient demand — they are pointers to investigate, not conclusions.

Largest-dispensing NHS Trusts — March 2026

By indicative spend. The top of this table is dominated by large teaching hospitals and Trusts that act as regional hubs for high-cost and homecare medicines.

#	NHS Trust	Region	Spend
1	Royal Free London Nhs Foundation Trust	London	£95.6m
2	Guy'S And St Thomas' Nhs Foundation Trust	London	£79.9m
3	Leeds Teaching Hospitals Nhs Trust	North East and Yorkshire	£72.5m
4	East Suffolk And North Essex Nhs Foundation Tr	East of England	£67.3m
5	University Hospitals Birmingham Nhs Foundation	Midlands	£58.5m
6	Manchester University Nhs Foundation Trust	North West	£57.3m
7	Sheffield Teaching Hospitals Nhs Foundation Tr	North East and Yorkshire	£54.8m
8	The Newcastle Upon Tyne Hospitals Nhs Foundati	North East and Yorkshire	£50.1m
9	Barts Health Nhs Trust	London	£47.2m
10	Cambridge University Hospitals Nhs Foundation	East of England	£47.1m
11	University College London Hospitals Nhs Founda	London	£47.1m
12	Nottingham University Hospitals Nhs Trust	Midlands	£45.4m
13	King'S College Hospital Nhs Foundation Trust	London	£39.5m
14	University Hospitals Of Leicester Nhs Trust	Midlands	£38.0m
15	University Hospital Southampton Nhs Foundation	South East	£37.3m
16	Oxford University Hospitals Nhs Foundation Tru	South East	£36.4m
17	University Hospitals Bristol And Weston Nhs Fo	South West	£36.4m
18	Northern Care Alliance Nhs Foundation Trust	North West	£36.0m
19	Imperial College Healthcare Nhs Trust	London	£34.1m
20	The Christie Nhs Foundation Trust	North West	£34.0m

The full league table of all 191 Trusts is available to download alongside this snapshot.

About this data

Source: Secondary Care Medicines Data (SCMD), NHS England / NHS Business Services Authority, under the Open Government Licence v3.0. Covers medicines dispensed by NHS hospital (secondary-care) pharmacies in England only — not primary care, private prescriptions, or the other UK nations.

Caveats: the data is only as good as what each organisation records, and the latest months are provisional and subject to revision. Errors and anomalies occur (mis-coded products, outlier quantities, negative/credit entries). In this free snapshot we have excluded the most obvious anomalies (for example, large negative 'credit' entries) but have not otherwise cleaned the data; in our commissioned client reports we identify, clean and correct such errors before drawing conclusions. Cost figures are indicative only (list-price based) and do not reflect the confidential discounts NHS Trusts actually pay. Month-on-month comparisons are affected by the differing number of days in each month.

RxLens is an independent service and is not affiliated with, endorsed by, or connected to NHS England or the NHSBSA. RxLens is a product of Nexcea Limited.